FDA plans ultra-fast review of three psychedelic drugs following Trump directive

Chronological Source Flow
Back

AI Fusion Summary

The FDA announced ultra‑fast review for three psychedelic drugs targeting hard‑to‑treat mental health conditions, including depression, following President Trump’s executive order to accelerate access and relax restrictions. Priority review vouchers were awarded to two psilocybin developers and one methylone developer.
24/04 17:04 wdrb.com
6 Πηγές
24/04 17:22 whdh.com
24/04 17:45 adn.com
24/04 18:30 newsweek.com
Comments
Loading...
0